ClinicalTrials.gg
CompletedNCT00688428Updated Mar 12, 2009

Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination

A Phase 1 interventional study of Esomeprazole 40mg/ASA 325mg and Esomeprazole in Ulcers and Upper GI Symptoms, sponsored by AstraZeneca. Completed. Open to participants aged 20 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-03-12.

Sponsored by AstraZeneca · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Study summary

The purpose of this study is to test if fixed dose esomeprazole and ASA capsule is pharmaceutically equal to a free combination of esomeprazole capsule and ASA tablet

02

Conditions studied

  • Ulcers
  • Upper GI Symptoms

Browse trials for

Keywords

  • esomeprazole
  • upper gi symptoms
  • low dose Aspirin treatment
03

In context

Ulcer

359 studies on the registry are indexed under Ulcer; 60 are open to participants now.

This study's planned enrollment of 84 is above the median of 65 across 291 interventional studies indexed under Ulcer.

Browse Ulcer studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • of 19-29kg/m2, inclusive
  • Weight of 50-95kg, inclusive
  • Clinically normal physical findings and laboratory values including , , and , as judged by the Investigator

Exclusion criteria

Exclusion Criteria:

  • Significant clinical illness within the 2 weeks preceding the first dose of products, as judged by the Investigator
  • History of mental, cardiac, renal, hepatitis, neurological, or significant gastrointestinal disease, as judged by the Investigator
  • Condition which could modify the absorption of the investigational products, as judged by the Investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    1

    combination capsule of Esomeprazole 40mg + ASA 325mg

    Drug: Esomeprazole 40mg/ASA 325mg

  • Experimental
    2

    Esomeprazole 40 mg capsule and ASA 325 mg tablet

    Drug: Esomeprazole · Drug: ASA

Interventions

  • DrugEsomeprazole 40mg/ASA 325mg

    Drug page: Esomeprazole

    combination capsule, administered as a single oral dose

    Also known as: Nexium/Bayer Aspirin

  • 40mg capsule, administered as a single dose

    Also known as: Nexium

  • DrugASA

    325mg tablet, administered as a single oral dose

    Also known as: Bayer aspirin

06

What researchers measure

Primary outcomes

  1. Samples for measurement of esomeprazole, ASA, and SA concentrations

    Time frame: Day 1 of each period

Secondary outcomes

  1. Fasting blood samples for determination of clinical chemistry and hematology parameters

    Time frame: screening and follow up visit

  2. urine samples for urinalysis parameters

    Time frame: screening, Period 1, and follow-up visit

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2008
First posted
Jun 3, 2008
Start
Apr 2008
Primary completionActual
Apr 2008
CompletionActual
Apr 2008
Last update
Mar 12, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00688428
Lead sponsor
AstraZeneca
First posted
Jun 3, 2008
Start date
Apr 2008
Primary completion
Apr 2008
Completion
Apr 2008
Last update
Mar 12, 2009

Study contacts

Jörgen Naesdal, M.D.
study director · AstraZeneca
Christopher Billings ., D.O
principal investigator · Biokinetics Clinical Applications

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esomeprazole · Aspirin

Start the discussion